Trevi Therapeutics (TRVI)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Trevi Therapeutics (TRVI)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Key Insights
Critical company metrics and information
Share Price
$2.76Market Cap
$212.15 MillionTotal Outstanding Shares
76.87 Million SharesTotal Employees
27Dividend
No dividendIPO Date
May 3, 2019SIC Description
Pharmaceutical PreparationsHomepage
https://www.trevitherapeutics.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities, Continuing | $-35.06 Million |
Net Cash Flow From Financing Activities, Continuing | $9.96 Million |
Net Cash Flow From Investing Activities | $15.19 Million |
Net Cash Flow From Financing Activities | $9.96 Million |
Net Cash Flow, Continuing | $-9.91 Million |
Net Cash Flow From Operating Activities | $-35.06 Million |
Net Cash Flow | $-9.91 Million |
Net Cash Flow From Investing Activities, Continuing | $15.19 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Available To Common Stockholders, Basic | $-44.32 Million |
Research and Development | $36.57 Million |
Operating Income/Loss | $-48.21 Million |
Basic Earnings Per Share | $0.44 |
Operating Expenses | $48.21 Million |
Revenues | $0.00 |
Income/Loss From Continuing Operations Before Tax | $-44.34 Million |
Diluted Average Shares | $100.77 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income Tax Expense/Benefit | $28000.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Diluted Earnings Per Share | $0.44 |
Net Income/Loss | $-44.32 Million |
Income/Loss From Continuing Operations After Tax | $-44.32 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Parent | $-44.32 Million |
Other Operating Expenses | $11.65 Million |
Nonoperating Income/Loss | $3.87 Million |
Basic Average Shares | $100.77 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Accounts Payable | $1.61 Million |
Assets | $68.91 Million |
Other Non-current Assets | $1.40 Million |
Other Current Assets | $66.16 Million |
Liabilities And Equity | $68.91 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Liabilities | $9.12 Million |
Current Assets | $67.34 Million |
Equity | $58.97 Million |
Liabilities | $9.94 Million |
Equity Attributable To Parent | $58.97 Million |
Noncurrent Liabilities | $816000.00 |
Other Current Liabilities | $7.51 Million |
Prepaid Expenses | $1.18 Million |
Fixed Assets | $174000.00 |
Noncurrent Assets | $1.57 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.